Navigation Links
Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients
Date:10/27/2011

BALTIMORE, Oct. 27, 2011 /PRNewswire/ -- Ameritox (SM), the nation's leader in Pain Medication Monitoring Solutions®, earlier this month submitted a Statement for the Record for the Congressional hearing on "Costs of Prescription Drug Abuse in the Medicare Part D Program," pointing to medication monitoring as a potential solution to improving adherence to pain medication, preventing drug diversion and aiding in lowering national healthcare costs. The hearing was held by the United States Senate Committee on Homeland Security and Government Affairs Subcommittee on Federal Financial Management, Government Information, Federal Services and International Security.

"As the nation's leader in Pain Medication Monitoring Solutions, Ameritox is committed to helping state and Federal policymakers understand the reasons behind rising prescription drug abuse, and identifying proven and cost-effective solutions," said Dr. Harry Leider, chief medical officer, Ameritox. "Medication monitoring is a critical tool in helping physicians provide the best possible care for patients. This simple, scientific tool can help assure doctors that the proper medications are getting to the millions of chronic pain patients who need it, and not contributing to misuse, abuse and diversion of prescription opioid therapy, costing payers millions of dollars each year."

Multiple studies have shown that medication monitoring, along with improving patient care, has the added benefit of reducing healthcare costs. One study published in The American Journal of Managed Care in January found that patients on chronic opioid therapy who were likely non-adherent, as determined by urine drug testing results, had 14 percent higher health care costs and 35 percent more hospital days. The same study found that patients who may be adherent to their opioid regimen had annual costs that were approximately 12 percent lower than non-adherent patients.

Dr. David Nash, dean of the Jefferson School of Population Health at Thomas Jefferson University in Philadelphia, PA, said such studies demonstrate that drug monitoring that uses advanced laboratory technologies is becoming a standard of care because it is a key component to quality care for patients on long-term opioid therapy.

"Addressing chronic pain and improving adherence to opioid therapy presents us with a major opportunity to raise the quality of care and reduce healthcare costs at the same time," Nash said.

About Ameritox

Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx Guardian (SM) – with Rx Guardian CD (SM), the only pain medication screening with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter@Ameritox, or on Facebook at facebook.com/ameritox.

© 2011 Ameritox Ltd. All rights reserved. AMERITOX, the AMERITOX logos, AMERITOX AUTOREMINDER, AMERITOX MEDICATION MONITORING SOLUTIONS, AMERITOX UNIVERSITY, PAIN MEDICATION MONITORING SOLUTIONS, POWERED BY YOUR NEED TO KNOW and PROTECT YOUR PATIENTS. PROTECT YOUR PRACTICE. RX GUARDIAN, RX GUARDIAN CD, and RX GUARDIAN AUTOREMINDER are trademarks of Ameritox.

For more information, contact: Lon Wagner
Ameritox
336-387-7742
Lon.Wagner@ameritox.com


'/>"/>
SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
2. Ameritox® Continues to Advance Industry Leadership
3. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
6. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
7. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):